FY2025 EPS Estimates for Omeros Reduced by Cantor Fitzgerald

Omeros Co. (NASDAQ:OMER) – Stock analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Omeros in a report released on Wednesday, April 2nd. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings per share of ($2.19) for the year, down from their previous forecast of ($1.73). The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros’ FY2025 earnings at ($2.19) EPS.

OMER has been the subject of a number of other reports. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Tuesday. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Tuesday. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Trading Down 4.1 %

OMER opened at $7.06 on Friday. The company has a 50 day moving average of $8.56 and a 200 day moving average of $7.63. Omeros has a 12 month low of $2.97 and a 12 month high of $13.60. The company has a market cap of $409.93 million, a PE ratio of -3.06 and a beta of 2.35.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of OMER. Truvestments Capital LLC grew its stake in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Omeros during the fourth quarter valued at about $46,000. BNP Paribas Financial Markets lifted its stake in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the last quarter. Finally, Picton Mahoney Asset Management boosted its holdings in shares of Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 4,404 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.